BRAIN Biotech AG
BNN.DEDrugs in Pipeline
4
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Q1 2027
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
Testosterone
Hypoactive Sexual Desire Disorder
Sildenafil
Hypoactive Sexual Desire Disorder
INS-GSH
Parkinson Disease
0.5 mgTestosterone + 10 mg Buspirone
Hypoactive Sexual Desire Disorder
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Testosterone | Phase 2 | Hypoactive Sexual Desire Disorder | - | - |
Sildenafil | Phase 2 | Hypoactive Sexual Desire Disorder | - | - |
INS-GSH | Phase 2 | Parkinson Disease | - | - |
0.5 mgTestosterone + 10 mg Buspirone | Phase 2 | Hypoactive Sexual Desire Disorder | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in BRAIN Biotech AG's drug pipeline?→
CatalystAlert tracks 4 drug candidates in BRAIN Biotech AG's (BNN.DE) pipeline across Phase 2. Its lead program is Testosterone (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is BRAIN Biotech AG's next FDA catalyst?→
BRAIN Biotech AG's (BNN.DE) next tracked catalyst is a Phase 2 expected January 1, 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track BNN.DE biotech catalysts?→
Add BNN.DE to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow BRAIN Biotech AG's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.